Abstract
Many advanced tumors produce excess amounts of Transforming Growth Factor-β (TGF-β), which is a potent growth inhibitor of normal epithelial cells. However, in tumors its homeostatic action on cells can be diverted along several alternative pathways. Thus, TGF-β signaling has been reported to elicit a preventative or tumor suppressive effect during the earlier stages of tumorigenesis, but later in tumor development, when carcinoma cells become refractory to TGF-β-mediated growth inhibition, response to TGF-β signaling elicits predominantly tumor progressing effects. This is not a simple switch from suppression to progression, but more like a rheostat, involving multiple complementary and antagonizing activities that slowly tip the balance from one to the other. This review will focus on the multiple activities of TGF-β in regulation of two epithelial tumor types, namely squamous cell carcinoma and breast cancer. Basic findings in current mouse models of cancer are presented, as well as a discussion of the complicating issue of outcome of altered TGFβ signaling depending on genetic variability between mouse strains. This review also discusses the role TGF-β within the tumor microenvironment particularly its ability to polarize the microenvironment towards a pro-tumorigenic milieu.
Keywords: TGF-β, tumor microenvironment, breast cancer, epithelial cells, pro-tumorigenic milieu, squamous cell carcinoma, epithelial, hematopoietic, immune cells, malignant carcinoma, epithelial to mesenchymal transformation (EMT), multi-stage tumorigenesis model, lymph nodes and lungs, immature state, bone metastasis
Current Pharmaceutical Biotechnology
Title: The Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis
Volume: 12 Issue: 12
Author(s): Erin C. Connolly and Rosemary J. Akhurst
Affiliation:
Keywords: TGF-β, tumor microenvironment, breast cancer, epithelial cells, pro-tumorigenic milieu, squamous cell carcinoma, epithelial, hematopoietic, immune cells, malignant carcinoma, epithelial to mesenchymal transformation (EMT), multi-stage tumorigenesis model, lymph nodes and lungs, immature state, bone metastasis
Abstract: Many advanced tumors produce excess amounts of Transforming Growth Factor-β (TGF-β), which is a potent growth inhibitor of normal epithelial cells. However, in tumors its homeostatic action on cells can be diverted along several alternative pathways. Thus, TGF-β signaling has been reported to elicit a preventative or tumor suppressive effect during the earlier stages of tumorigenesis, but later in tumor development, when carcinoma cells become refractory to TGF-β-mediated growth inhibition, response to TGF-β signaling elicits predominantly tumor progressing effects. This is not a simple switch from suppression to progression, but more like a rheostat, involving multiple complementary and antagonizing activities that slowly tip the balance from one to the other. This review will focus on the multiple activities of TGF-β in regulation of two epithelial tumor types, namely squamous cell carcinoma and breast cancer. Basic findings in current mouse models of cancer are presented, as well as a discussion of the complicating issue of outcome of altered TGFβ signaling depending on genetic variability between mouse strains. This review also discusses the role TGF-β within the tumor microenvironment particularly its ability to polarize the microenvironment towards a pro-tumorigenic milieu.
Export Options
About this article
Cite this article as:
C. Connolly Erin and J. Akhurst Rosemary, The Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis, Current Pharmaceutical Biotechnology 2011; 12 (12) . https://dx.doi.org/10.2174/138920111798808284
DOI https://dx.doi.org/10.2174/138920111798808284 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proinflammatory Cytokines in Breast Cancer: Mechanisms of Action and Potential Targets for Therapeutics
Current Drug Targets Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Double-Faced Role of Human Mesenchymal Stem Cells and their Role/Challenges in Cancer Therapy
Current Stem Cell Research & Therapy Targeting Translation for Treatment of Cancer - A Novel Role for IRES?
Current Cancer Drug Targets Mucoadhesive Propolis Gel for Prevention of Radiation-Induced Oral Mucositis
Current Clinical Pharmacology Recent Patents on Biomarkers in Oral Cancers
Recent Patents on Biomarkers S100A8 and S100A9 Overexpression Is Associated with Poor Pathological Parameters in Invasive Ductal Carcinoma of the Breast
Current Cancer Drug Targets Nitric Oxide in Health and Disease from the Point of View of the Otorhinolaryngologist
Current Pharmaceutical Design The Anti-tumor Activity and Mechanisms of rLj-RGD3 on Human Laryngeal Squamous Carcinoma Hep2 Cells
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer
Current Cancer Drug Targets Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Nitric Oxide Synthase and Cyclooxygenase Pathways: A Complex Interplay in Cellular Signaling
Current Medicinal Chemistry Targeting Microenvironment of Melanoma and Head and Neck Cancers in Photodynamic Therapy
Current Medicinal Chemistry Need to Think Outside Organ-based Diagnosis to Molecular Diagnostics
Applied Clinical Research, Clinical Trials and Regulatory Affairs Emerging Therapeutic Agents for Cervical Cancer
Recent Patents on Anti-Cancer Drug Discovery Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiating Between Primary Tumor, Metastatic Node and Normal Tissue in Head and Neck Cancer
Current Medical Imaging Molecular Dynamics in Esophageal Adenocarcinoma: Who’s in Control?
Current Cancer Drug Targets A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
Current Cancer Drug Targets The Antimitotic Potential of PARP Inhibitors, An Unexplored Therapeutic Alternative
Current Topics in Medicinal Chemistry Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry